Molecular response in CML: where is the bar?

Molecular response prediction in CML: novel ideas?

Since the introduction of tyrosine kinase inhibitor imatinib, the first targeted cancer therapy, survival of Chronic Myelogenous Leukemia (CML) patients has approached that of the normal population [1]. Treatment with TKI leads to reduction of malignant cells by several orders of magnitude, sometimes even below the level of detection of very sensitive molecular assays. Thus, in recent years ach...

Where is Patient Safety Research and Practice Heading? A Response to Recent Commentaries

where is the problem?

where is the problem? health scientists are constantly trying to support people by diagnosing, managing the diseases, and improving health in all possible dimensions. attention has been drawn to all aspects of health including biological, psychological, social and spiritual. the problem may lay in behavior, clinical issues, organ cites, genome and epigenome. thus it falls on us, the medical soc...

Predicting response in CML.

study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Predicting response in chronic myeloid leukemia (CML) patients who are offered tyrosine kinase inhibitor (TKI) second-line therapy is vital...

Hematological and molecular response evaluation of CML patients on imatinib.

BACKGROUND The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. AIMS To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. M...